# US 2003/0077322 A1 · Solid dispersion system of pranlukast with improved dissolution and method for preparing the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0077322 A1
- Document ID: US20030077322A1
- Status: Published application
- Kind: A1
- Application number: 10/300,299
- Filed: 2002-11-19
- Published: 2003-04-24
- Earliest claimed: 2000-05-20
- Inventors: Sang Deuk Lee
- Web page: https://patentgrep.com/patent/US20030077322A1

## CPC

- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition of pranlukast having improved bioavailability is disclosed. The composition is formulated as a solid dispersion, preferably for oral administration. In one embodiment, the invention comprises an amount of pranlukast uniformly dispersed in an inert polymer carrier comprising at least one of hydroxypropylmethylcellulose or hydroxypropylcellulose. In another embodiment, the composition further comprises an amount of hydroxypropylmethylcellulose phthalate-50. A method for preparing the composition, an oral formulation comprising the composition, and methods of treating bronchial asthma and allergic rhinitis with the composition are also disclosed.

## Claims

### Claim 1

A pharmaceutical composition comprising an amount of pranlukast (4-oxo-8-[4-(4-phenylbutoxy)benzoyl-amino]-2-(tetrazol-5-yl)-4H-1-benzopyran hemihydrate) uniformly dispersed in a solid state inert polymer carrier comprising at least one of hydroxypropylcellulose (“HPC”) or hydroxypropylmethylcellulose (“HPMC”).

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the weight ratio of the polymer carrier to pranlukast is within a range of 0.25:1 to 5:1.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, wherein the weight ratio of the polymer carrier to pranlukast is within a range of 0.5:1 to 3:1.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, further comprising an amount of hydroxypropylmethylcellulose phthalate 50 (“HPMC-50”).

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the weight ratio of HPMC-50 to the at least one of HPC and HPMC is within a range of 0.1:1 to 4:1.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, wherein the weight ratio of HPMC-50 to the at least one of HPC and HPMC is within a range of 0.25:1 to 2:1.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, formulated for oral administration.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, formulated as tablets, capsules, granules or a dry syrup.

### Claim 9

A solid dispersion formulation for oral administration consisting essentially of a pharmaceutical composition comprising an amount pranlukast uniformly dispersed in a solid state inert polymer carrier comprising at least one of HPC or HPMC.

### Claim 10 (depends on 9)

The solid dispersion formulation for oral administration of claim 9, wherein the weight ratio of the polymer carrier to pranlukast is within a range of 0.25:1 to 5:1.

### Claim 11 (depends on 9)

The solid dispersion formulation for oral administration of claim 9, wherein the pharmaceutical composition further comprises an amount of HPMC-50.

### Claim 12 (depends on 11)

The solid dispersion formulation for oral administration of claim 11, wherein the weight ratio of HPMC-50 to the at least one of HPC and HPMC is within a range of 0.1:1 to 4:1.

### Claim 13 (depends on 9)

The solid dispersion formulation for oral administration of claim 9, formulated as tablets, capsules, granules or a dry syrup.

### Claim 14 (depends on 9)

The solid dispersion formulation for oral administration of claim 9, further comprising one or more additional components chosen from surfactants, preservatives, complex-forming agents, electrolytes, discharging agents and other active ingredients compatible with pranlukast.

### Claim 15 (depends on 14)

The solid dispersion formulation for oral administration of claim 14, wherein the one or more additional components is chosen from steroids, bronchodilators, antitussives and expectorants.

### Claim 16 (depends on 9)

A method of treating bronchial asthma in a patient, comprising administering to a patient in need of treatment for bronchial asthma, a therapeutically effective dosage of a solid dispersion formulation according to claim 9.

### Claim 17 (depends on 9)

A method of treating allergic rhinitis in a patient, comprising administering to a patient in need of treatment for allergic rhinitis, a therapeutically effective dosage of a solid dispersion formulation according to claim 9.

### Claim 18

A method for preparing a solid dispersion formulation consisting essentially of a pharmaceutical composition comprising pranlukast uniformly dispersed in a solid state inert polymer carrier comprising at least one of HPC or HPMC, the method comprising:
a) dissolving the pranlukast and the solid state inert polymer carrier in a liquid solvent mixture of dichloromethane (“DCM”) and methanol (“MeOH”); and
b) drying the solvent to obtain a solid dispersion of pranlukast in the polymer carrier.

### Claim 19 (depends on 18)

The method of claim 18, wherein the volume ratio of DCM:MeOH in the liquid solvent mixture is within a range of 2:1 to 5:1.

### Claim 20 (depends on 19)

The method of claim 19, wherein the volume ratio of DCM:MeOH in the liquid solvent mixture is within a range of 3:1 to 4.5:1.
